HIV liver disease drug trial halted early
NCT ID NCT05211284
Summary
This study aimed to test if a drug called saroglitazar magnesium could reduce liver fat in people living with HIV who also have fatty liver disease (NAFLD). It was a Phase 2 trial that planned to compare the drug against a placebo using MRI scans to measure liver fat. The study was terminated early by the sponsor after enrolling only 4 participants, due to changes in the company's research focus.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zydus US001
Durham, North Carolina, 27710, United States
-
Zydus US002
Indianapolis, Indiana, 46202, United States
-
Zydus US003
Baltimore, Maryland, 21287, United States
-
Zydus US004
Birmingham, Alabama, 35294-2050, United States
-
Zydus US005
La Jolla, California, 92037, United States
-
Zydus US006
San Francisco, California, 94143, United States
-
Zydus US007
Houston, Texas, 77030, United States
-
Zydus US008
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.